Top scientists gather for meeting on groundbreaking advances and pioneering innovations in cell-based therapeutic approaches to cardiovascular diseases.

WHAT: The Fifth International Conference on Cell Therapy for Cardiovascular Disease (IC3D) is a three-day comprehensive program dedicated to the evolving field of cell-based therapies for treating cardiovascular diseases. The theme of this year's meeting is "Cellular and Molecular Building Blocks: Strategies for Cardiovascular Reconstruction in 2009."

WHY: Leaders in the field will convene to present basic, core discussions on stem cell science as well as their work, experiences, observations, and opinions on the benefits and drawbacks of the field. The 2009 meeting will encompass a broad range of cell-based therapeutic approaches to cardiovascular disease.

Research presented at IC3D will touch on topics such as: Clinical studies of stem cell repair of the heart, brain and peripheral arteries

New sources of adult stem cells

Status of embryonic stem cell research

Molecular signaling and cellular responses

Models of acute and chronic myocardial injury

Methods for application of stem cell products

Engineered tissue including in vitro and in vivo studies

Imaging and other assessment methods New sessions for 2009 will include: Focus on peripheral vascular disease

An in-depth view of stem cell effects and how to best assess disease states

The convergence of cell and tissue modification as methods for enhancing the biologic effects of molecular and cellular agents WHO: Warren Sherman, M.D., Conference Director, is Director of Cardiac Cell-Based Endovascular Therapies at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital and Columbia University Medical Center. Dr. Sherman is a renowned clinical investigator in the field of myocardial regeneration who pioneered a technique for injecting stem cells into the heart. In Rotterdam in May 2001, he performed the first catheter-based injection of stem cells into the heart of a patient with congestive heart failure due to a previous heart attack. At Columbia University Medical Center, researchers led by Dr. Sherman are using the patient's own myoblasts -- progenitor cells found in muscle -- to repair and replace injured cardiac tissue in a process called myogenesis. Dr. Sherman collaborates in studies to improve the outcomes of cell implantation with colleagues at Columbia University Medical Center, all of whom will be presenting their research at the conference.

WHEN: January 13 - 16, 2008

WHERE: The New York Academy of Medicine, New York, NY


For more information visit: crf/Cell_Therapy/

About CRF

The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1990, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in the subspecialty of interventional cardiology and endovascular medicine.

Source: Judy Romero
Cardiovascular Research Foundation

Tag Cloud